Dev Prasad
Stock Analyst at LUCID CAPITAL MARKETS
(3.03)
# 1,315
Out of 5,150 analysts
6
Total ratings
60%
Success rate
82.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma | Downgrades: Neutral | $11 → $1 | $0.96 | +3.68% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiates: Buy | $4 | $0.30 | +1,223.19% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $5 | $4.57 | +9.41% | 1 | Jun 17, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $24 | $18.36 | +30.72% | 1 | Dec 17, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $6 | $2.83 | +112.01% | 1 | Dec 17, 2024 | |
| CALC CalciMedica | Initiates: Buy | $13 | $0.62 | +1,983.33% | 1 | Dec 17, 2024 |
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: $11 → $1
Current: $0.96
Upside: +3.68%
Cue Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $4
Current: $0.30
Upside: +1,223.19%
Opus Genetics
Jun 17, 2025
Initiates: Buy
Price Target: $5
Current: $4.57
Upside: +9.41%
Avalo Therapeutics
Dec 17, 2024
Initiates: Buy
Price Target: $24
Current: $18.36
Upside: +30.72%
iBio, Inc.
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.83
Upside: +112.01%
CalciMedica
Dec 17, 2024
Initiates: Buy
Price Target: $13
Current: $0.62
Upside: +1,983.33%